1Davis HL, Michel ML, Whalen RG. DNA- based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody[J]. Hum Mol Genet, 1993, 2( 11 ) : 1847 - 1851.
2Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety mid immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device[J]. Vaccine, 1999, 17(22) :2826- 2829.
3Roy MJ, Wu MS, Barr L J, et al. Induction of antigen-specific CD8^+ T cells, T helper cells, and protective levels of antibody in human by particle- mediated administration of a hepatitis B virus DNA vaccine [ J ].Vaccine, 2000, 19(7 - 8) :764 - 778.
4Swain WE, Heydenburg Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B [J]. Dev Biol (Basel), 2000, 104:115- 119.
5Michel ML, Pol S, Breehot C, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future [J]. Vaccine, 2001, 19 : 2395 - 2399.
6Schmaljohn C, Vanderzanden L, Bray M, et al. Maked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge[J]. J Virol, 1997, 71:9563 - 9569.
7Singh M, Briones M, Ott G, et al. Cationic microparticles: A potent delivery system for DNA vaccines [J]. Proc Natl Acad Sci USA, 2000, 97 :811 -816.
8Wang R, Doolan DL, Le TP, et al. Induction of antigen - specific cytotoxic Tlymphocytes in humans by a malaria DNA vaccine [J]. Science, 1998, 282:476-480.
9MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA - based vaccine for trestment of human immunodeficiency virus type 1 infection:safety and host response[J]. J Infect Dis, 1998, 178:92- 100.
10Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV - 1 - infected patients [J]. Lancet, 1998, 351:1320- 1325.
同被引文献9
1Tuberculosis Research Center.Fifteen-year follow-up trail of BCG vaccines in south India for tuberculosis prevention.Ind J Med Res,1999,110:56.
2Okkels LM,Doherty TM,Andersen PS.The components for a safe and efficient tuberculosis subunit vaccine-Recent progress and post-genomic insights.Current Pharmac Biotech,2003,15:69-83.
3Hanson MS,Lapcevich CV,Haun SL.Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery.Ann NY Acad Sci,1995,754:214-221.
4Suzanne MHW,Vasan KS,William RJ.Survival perspectives from the world's most successful pathogen,Mycobacterium tuberculosis.Nat Immunol,2003,4:949-955.
5Jacobs GG,Johnson JL,Boom WH,et al.Tuberculosis vaccines:how close to human testing? Tubercul and Lung Dis,1997,78:159.
6Huygen K.DNA vaccines:Application to tuberculosis.Int J Tuberc Lung Dis,1998,2:971.
7Lowrie DB,Tascon RE,Colston MJ,et al.Towards a DNA vaccine against tuberculosis.Vaccine,1994,12:1537-1540.
8Fuller JT,Macklin M,Drape B,et al.Gene gun-mediated DNA immunization with HBsAg:efficacy in small and large animals.In:Brown F,Borton D,Doherty P,Mekalanos J,Norrby E,editors.Vaccines:Molecular Approaches to The Control of Infectious Disease.New York:Cold Spring Harbor Laboratory Press,1997,157-161.
